Generic drug companies like Mylan have been out of favor with investors for several years. It might finally be time to bet on a turnaround. Mylan, which reported first-quarter sales of $2.7 billion and adjusted earnings of $0.96 a share on Wednesday morning, looks especially interesting. Those figures, down 1% and up 3% from a year earlier, respectively, were hardly spectacular.

Source: Wall Street Journal May 09, 2018 17:02 UTC